INCYTE CORP
Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.
The FDA approved Incyte Corp's Atebrioz for a rare bone disorder, expanding its portfolio. The company's stock is modestly overvalued by 17.9% according to GF Value™, with a current price of $124.68. Incyte has a strong GF Score™ of 87/100, indicating robust financial health and operational performance.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning INCY (INCYTE CORP). Coverage has skewed bullish: 7 bullish, 1 neutral, and 0 bearish.
Recent INCY coverage spans regulation, technology and corporate actions.
In the last 30 days, INCY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($2.8M). The most active reporter was CAGNONI PABLO J, President, Global Head of R&D, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Voucher adds a valuable asset for Incyte, supporting its valuation.
The voucher can be sold or used for future filings, providing a financial windfall for Incyte.
The approval adds a first‑in‑class therapy for a rare disease, expanding Incyte's pipeline and potential sales.
Potential launch could boost INCY shares as the first oral HS therapy.
Mirum's FDA outcome directly affects Incyte's royalty and milestone upside.
AlphAI scores every news story that mentions INCY with an AI model for sentiment and relevance, and aggregates insider trades from INCYTE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.
3 min readMirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.
3 min readThe FDA approved Incyte Corp's Atebrioz for a rare bone disorder, expanding its portfolio. The company's stock is modestly overvalued by 17.9% according to GF Value™, with a current price of $124.68. Incyte has a strong GF Score™ of 87/100, indicating robust financial health and operational performance.
2 min readThe EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.
2 min readMerck (MRK) awaits FDA decision on Winrevair for pulmonary arterial hypertension. Mirum (MIRM) faces decision on Zilurgisertib for FOP, with Incyte (INCY) holding economic interest. Grail (GRAL) has FDA advisory committee review for Galleri multi-cancer blood test. MRK up 40%, INCY up 23%, MIRM up 17.6%, GRAL down 9%.
2 min readSpecialised Therapeutics (ST) expanded its partnership with Incyte (NASDAQ: INCY) to commercialize, distribute, and register ruxolitinib cream (Opzelura®) in Australia. ST will handle regulatory, marketing, and distribution, while Incyte retains development and manufacturing. Opzelura is approved for treating vitiligo and atopic dermatitis in the U.S. and EU. ST aims to navigate regulatory pathways for Australian approval.
2 min readIncyte (NASDAQ:INCY) projects $4B sales target, with JAKAFI to XR conversion preserving up to $750M. The company advances pipeline, including 989 for myelofibrosis, 734 for pancreatic cancer, and 890 for colorectal cancer. Preclinical data on next-gen therapies to be presented at ASH and ESMO. Povorcitinib for hidradenitis suppurativa and von Willebrand disease treatments also in development.
3 min readIncyte (INCY) announced that MINJUVI, a treatment for relapsed or refractory follicular lymphoma, is now funded in Ontario through the FAST Program, providing earlier patient access. This decision may influence demand and operational visibility for Incyte's oncology portfolio. The company projects $5.8B revenue and $1.2B earnings by 2029, with analysts divided on its growth prospects and risks, including competition and R&D spending.
3 min readInsiders sold shares in AFLAC, CME, Incyte, Box, and Five Below. Japan Post sold 55,700 AFLAC shares for $6.34M. CME director sold 500 shares for $140,055. Incyte EVP sold 23,218 shares for $2.8M. Box director sold 6,158 shares for $215,530. Five Below insiders sold 6,318 shares for $1.57M.
2 min readCAGNONI PABLO J (President, Global Head of R&D) sold 23,218 shares of INCYTE CORP (INCY) at an average of $120.49 ($120.49–$120.50, $2.80M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min read
